SCHEMBL15728294

SCHEMBL15728294

COc1cc(OC)c(F)c(COc2cnc(Nc3cc(CN4CCN(CCO)CC4)n[nH]3)nc2)c1F

nearest known ligand 0.56

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
▸ FGFR3 P22607 11/20 0.56
▸ FGFR1 P11362 9/20 0.56
▸ FGFR4 P22455 9/20 0.56
▸ FGFR2 P21802 1/20 0.56
▸ KCNH2 Q12809 7/20 0.53
▸ CYP3A4 P08684 2/20 0.41
▸ CYP2C9 P11712 2/20 0.41
▸ CYP2C19 P33261 2/20 0.41
▸ CYP2D6 P10635 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18132777 0.95 FGFR3 (0.51) FGFR3FGFR1FGFR4FGFR2KCNH2
SCHEMBL15244124 0.92 FGFR3 (0.58) FGFR3FGFR1FGFR4FGFR2KCNH2
SCHEMBL15728626 0.91 FGFR3 (0.51) FGFR3FGFR1FGFR4FGFR2KCNH2
SCHEMBL15728542 0.89 FGFR3 (0.55) FGFR3FGFR1FGFR4FGFR2KCNH2
SCHEMBL15244610 0.89 FGFR3 (0.48) FGFR3FGFR1FGFR4FGFR2KCNH2
SCHEMBL15709751 0.89 FGFR3 (0.51) FGFR3FGFR1FGFR4FGFR2KCNH2
SCHEMBL18132631 0.87 FGFR3 (0.53) FGFR3FGFR1FGFR4FGFR2KCNH2
SCHEMBL18132798 0.86 FGFR3 (0.47) FGFR3FGFR1FGFR4FGFR2KCNH2
SCHEMBL15709801 0.85 FGFR4 (0.55) FGFR3FGFR1FGFR4FGFR2KCNH2
SCHEMBL15244617 0.85 FGFR3 (0.47) FGFR3FGFR1FGFR4FGFR2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2821402-B1 NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND ASTELLAS PHARMA INC (JP) 2019-08-21 — — EP disclosed
US-20170152232-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND ASTELLAS PHARMA INC. (JP) 2017-06-01 — — US disclosed
US-9464077-B2 Nitrogen-containing aromatic heterocyclic compound ASTELLAS PHARMA INC. (JP) 2016-10-11 — — US disclosed
EP-2821402-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND Astellas Pharma Inc. (JP) 2015-01-07 — — EP disclosed
US-20140142084-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND KOTOBUKI PHARMACEUTICAL CO., LTD. (JP) 2014-05-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140142084-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND FGFR3, FGFR1, FGFR2 FGFR3 1/4885FGFR1 2/4885FGFR4 4/4885
US-20170152232-A1 NITROGEN-CONTAINING AROMATIC HETEROCYCLIC COMPOUND FGFR3, FGFR1, FGFR2 FGFR3 1/4885FGFR1 2/4885FGFR4 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback